Project Grant HT94252410195
Award Date
4/1/24
Completion Date
3/31/26
Dollars Obligated
$723K
Federal Agency
Defense Health Agency
Awardee
Dignity Health (SKX6AXF9ZTM3)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
The U.S. Department of Defense's Defense Health Agency awarded a $1,119,598 Project Grant to Dignity Health, doing business as St. Joseph's Hospital and Medical Center, for the research project "AD Genetic Risk as a Prognostic Factor for Cognitive Outcomes after TBI" under the Military Medical Research and Development program (CFDA 12.420). This 4-year award, effective from September 30, 2024 to September 29, 2028, will fund innovative biomedical research focused on understanding the...
This Project Grant award of $680,458.00 from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), is supporting Dignity Health's Mercy Hospital in San Francisco to conduct research on "ENHANCING ACMSD ACTIVITY AS A NOVEL GENE THERAPY FOR ALS." The research aims to transform healthcare for service members, veterans, and the public through innovative biomedical research on neurodegenerative diseases like amyotrophic lateral sclerosis...
This federal Project Grant award, totaling $655,380, was provided by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to Dignity Health's St. Joseph's Hospital and Medical Center (also known as Barrow Neurological Institute) to conduct research on maladaptive 5-HT raphe-corticolimbic plasticity underlying the development of non-motor symptoms in Parkinson's disease. The project will be performed in...
This $649,762 federal Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) supports research by Dignity Health's St. Joseph's Hospital and Medical Center (Barrow Neurological Institute) to investigate maladaptive 5-HT raphe-corticolimbic plasticity underlying the development of non-motor symptoms in Parkinson's disease. The award period runs from September 30, 2024 through September 29, 2028. As a prime recipient,...
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,487,072.00 to Dignity Health's St. Joseph's Hospital and Medical Center in Phoenix, AZ to develop a novel bifunctional agent as a radiosensitizer for glioblastoma and a radioprotector of normal brain. The award has an initial term from August 15, 2024 to August 14, 2027. The key products or services to be delivered through this funding include...
This federal Project Grant award, issued by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), provides $963,000.00 to The Regents of the University of California, doing business as University of California, Berkeley, to conduct research on "REBALANCING C9ORF72 LOSS OF FUNCTION IN AMYOTROPHIC LATERAL SCLEROSIS". The research, which will take place over a two-year period from March 1, 2024 to February 28, 2026, aims to...
The Defense Health Agency awarded a $1.19 million Project Grant to The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. from May 1, 2023 to April 30, 2026 under the Military Medical Research and Development program (CFDA 12.420). The grant funds research into targeting excessive sphingolipid synthesis for treatment of amyotrophic lateral sclerosis (ALS) being conducted by Dr. Teresa M. Dunn of the Uniformed Services University of the Health Sciences. Dr. Dunn is...
The University of California, San Diego received a $694,650 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The two-year award will support research on RNA-directed therapy for amyotrophic lateral sclerosis (ALS) linked to the C9ORF72 gene using engineered zinc finger nucleases. The Military Medical Research and Development program aims to transform military and public health through...